The Solution Provider for 
Drug Discovery in Oncology

ProQinase is a leading contract research company for cancer drug discovery. The company has a long-standing scientific experience in cancer research with a focus on protein kinases and tumor angiogenesis.

Currently 301 in-house produced catalytically active protein kinases, 15 lipid kinases and 14 kinase substrates are offered for sale. Furthermore, 413 protein kinases and 17 lipid kinases are available for biochemical kinase assay services (HTS, selectivity profiling and IC50 determination).

Hits derived from biochemical kinase assays can be further characterized at ProQinase in cell-based, target-specific phosphorylation assays and in various functional cell-based assays like migration assays, proliferation assays, soft agar assays, and angiogenesis assays.

ProQinase’s portfolio of preclinical services is completed by in vivo testing services including subcutaneous tumor models (xenograft tumor models), orthotopic tumor models with in vivo and ex vivo bioluminescence analysis and a unique in vivo angiogenesis assay.

In addition, ProQinase provides custom-tailored solutions of preclinical services as support for cancer drug discovery projects.

cancer research, contract research, preclinical services, cancer drug discovery
Imprint | Copyright 2002-2015 ProQinase GmbH. All rights reserved.
Meet ProQinase at

The Immunotherapy of Cancer Conference (ITOC),
March 21-23, 2016 at Booth #B1, TU Munich, Germany

AACR Annual Meeting 2016,
April 16-20, 2016 at Booth #542, Ernest N. Morial Convention Center, New Orleans, Louisiana, USA

Home     Company     Products & Services     Science     Contact